Volume 1, 2007 - Online Edition | In This Issue
The results are in! >
ALR's 2007 grant recipients >
One Love. One Cause. ALR Gala a Smashing Success >
The Faces of Lupus >
Advocacy Update — ALR Goes to Washington >
Research Results - Rituximab Results in Long-Term Immune Alteration in Some Lupus Patients >
Research Results — Exploring Toll-Like Receptors’ (TLR) Role in Lupus >
Research Results – The Role of Myeloid Dendritic Cells in Lupus >
News Flash – American College of Rheumatology Annual Meeting Update >
FDA Warning on Rituximab >
Drug Research and Development News >
Beyond the Research - 2007 Walk Sites Announced >
The results are in!
After much discussion and evaluation, the Alliance for Lupus Research’s peer reviewers, Scientific Advisory Board, and Board of Directors have named 11 Pilot grantees for the 2007 Target Identification in Lupus (TIL) program, and renewed the grants of two others. They also awarded 10 additional grants under ALR’s new Pilot Grant initiative, for a total of nearly $8 million in funding.
“We are very excited about the potential of our largest class of grantees yet,” said ALR resident Barbara Boyts. “Our new investigators hail from dozens of the most prestigious research institutions around the world.”
As the largest private funder of lupus research in the world, the ALR has committed over $42 million to research since its founding in 1999.
For the latest information on ALR-funded investigators, please visit our website: www.lupusresearch.org/research_07.html